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A new national antimicrobial resistance surveillance 
program in Singapore public hospitals that uses WHO-
NET detected high levels of methicillin resistance among 
Staphylococcus aureus (35.3%), carbapenem resistance 
among Acinetobacter spp. (49.6%), and third-generation 
cephalosporin resistance among Klebsiella pneumoniae 
(35.9%) hospital isolates in 2006. Antimicrobial drug resis-
tance is a major problem in Singapore.
B
acterial antimicrobial drug resistance is a worldwide 
problem that is exacerbated by the diminishing number 
of new antimicrobial drugs in the pharmaceutical pipeline 
(1,2). This is an emerging public health problem, especially 
in hospitals of the newly industrialized countries of Asia 
and the Paciﬁ  c. In 2001, the World Health Organization 
(WHO) launched the ﬁ  rst global strategy to counter this 
phenomenon (3), a key component of which is the develop-
ment of surveillance programs to monitor trends in antimi-
crobial drug resistance and use (3).
Overarching surveillance programs monitoring anti-
microbial drug–resistance trends on a national or regional 
level are present in Australia (4) and Europe (5). Such is 
not the case in Singapore, where surveillance efforts have 
generally been conducted only at the institutional level, 
with limited sharing and analysis of data. As a result, the 
actual scale of local antimicrobial drug resistance is not 
well deﬁ  ned. The Network for Antimicrobial Resistance 
Surveillance (Singapore), a voluntary group of healthcare 
professionals, was established in December 2005 to ﬁ  ll this 
gap.
The Study
A laboratory-based surveillance program was estab-
lished in 2006 to monitor the antimicrobial drug–resistance 
trends of 6 common nosocomial pathogens: Staphylococ-
cus aureus, Escherichia coli, Enterococcus spp., Klebsiella 
pneumoniae, Pseudomonas aeruginosa, and Acinetobacter 
spp. Excluding coagulase-negative staphylococci, these or-
ganisms collectively account for >90% of positive bacterial 
cultures from nosocomial infections locally.
All 6 public sector acute-care hospitals in Singapore—
2 tertiary-care hospitals, 3 secondary-care hospitals, and 1 
institution dedicated to pediatrics and obstetrics/gyneco-
logic services only—participated in the program. These 
hospitals constitute ≈76.5% of the 8,205 acute-care hospi-
tal beds available in the country (6).
All clinical isolates submitted to the externally accred-
ited microbiology laboratories of these hospitals in calen-
dar year 2006 were recorded for this study. Four labora-
tories performed antimicrobial drug–susceptibility testing 
predominantly through disk-susceptibility testing, supple-
mented by VITEK 2 system (bioMérieux, Marcy l’Etoile, 
France), following guidelines of the Clinical Laboratory 
Standards Institute (CSLI) (7). One laboratory used the 
VITEK 2 system exclusively, following CLSI guidelines 
(7), and the sixth laboratory used disk-susceptibility test-
ing, following guidelines for the calibrated dichotomous 
sensitivity method (8). 
Microbiologic and demographic data were extracted 
every quarter from the laboratory information system of 
each participating institution and converted into a standard 
format by using WHONET 5 (WHO, Geneva, Switzerland). 
Data were collated and analyzed centrally, with duplicates 
eliminated according to CLSI guidelines (9). Hospital bed 
occupancy data were obtained from the published records 
of each institution.
Statistical analysis was performed by using Excel 2003 
(Microsoft, Redmond, WA, USA). Clinical microbiologists 
of the respective hospitals veriﬁ  ed the analyzed data. Com-
bined antimicrobial drug–susceptibility data were analyzed 
for the target organisms in 3 ways: for all isolates, for blood 
culture isolates only, and for isolates from intensive care 
unit (ICU) settings. The same analysis was also separately 
performed for data from each institution.
The distribution of resistant organisms isolated in 
2006 is shown in the Table. The incidence density of re-
sistant organisms from clinical samples for 2006 is shown 
in the Figure. Antimicrobial drug resistance was generally 
more prevalent in ICUs, but there was marked interhospital 
variation in resistance percentages. The tertiary hospitals 
had high rates of antimicrobial drug resistance, whereas the 
pediatric and women’s hospital had much lower rates.
Antimicrobial drug resistance in the Enterobacteriaceae 
was prevalent for amoxicillin-clavulanate (K. pneumoniae 
36.0%, E. coli 26.7%), ciproﬂ  oxacin, and third-generation 
cephalosporins (Table). Imipenem resistance was present 
in 0.2% (14 isolates) of K. pneumoniae. Ertapenem resis-
tance was reported in 0.2% of all E. coli isolates and 0.9% 
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of all K. pneumoniae isolates at the institutions that rou-
tinely test for this agent.
Despite the relatively small numbers of Acinetobacter 
spp. isolates compared with the other organisms, carbap-
enem-resistant Acinetobacter spp. were found in all ICUs 
at a high incidence density; as many as 69% of all isolates 
at 1 ICU were carbapenem resistant. Fully 18.2% of all 
Acinetobacter spp. were resistant to ampicillin/sulbactam, 
cephalosporins, carbapenems, ciproﬂ  oxacin, and aminogly-
cosides; these particular isolates were susceptible to only 
the polymyxins. Carbapenem resistance was also found in 
9.6% of all P. aeruginosa isolates and in up to 27.2% of 
ICU isolates.
Methicillin resistance occurred in 35.3% of all S. aure-
us isolates. Methicillin-resistant S. aureus (MRSA) strains 
showed correspondingly high resistance levels to macro-
lides (90.2%), ciproﬂ  oxacin (93.9%), and trimethoprim-
sulfamethoxazole (49.9%). Vancomycin resistance was 
reported in 0.8% of all enterococci.
Based on incidence density calculations, MRSA was 
the predominant drug-resistant pathogen at all hospitals. It 
had the highest incidence density for blood and ICU cul-
tures (0.31/1,000 inpatient-days and 4.48/1,000 ICU inpa-
tient-days, respectively) among all organisms surveyed. 
Third-generation cephalosporin-resistant K. pneumoniae 
was the predominant gram-negative resistant pathogen, 
with an incidence density of 0.19/1,000 and 3.21/1,000 in-
patient days for blood and ICU cultures, respectively.
A comparison between organisms isolated from blood 
cultures and other cultures demonstrated statistically sig-
niﬁ  cant differences with regard to percentage resistance for 
S. aureus, P. aeruginosa, and the Enterobacteriaceae. The 
reason for these ﬁ  nding is not evident. In general, ≈10% of 
all resistant organisms were isolated from blood cultures.
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Table. Drug-resistant clinical bacterial isolates cultured at public sector hospitals, Singapore, 2006* 
All resistant isolates Resistant blood isolates Resistant ICU isolates
Isolates
No. (%) of 
all isolates†
% Range for 
single
hospitals‡
No. (%) of 
all blood 
isolates†
% Range for 
single
hospitals‡
p
value§
No. (%) of  
all ICU 
isolates†
% Range for 
single
hospitals†
p
value¶
Methicillin-resistant 
S. aureus
3,517
(35.3)
18.0–44.3 497
(39.8)
23.8–44.4 <0.01 261
(46.7)
26.8–70.5 <0.01
Vancomycin-
resistant enterococci 
(E. faecium or E. 
faecalis)
31
(0.8)
0–1.3 5
(1.3)
0–2.4 0.25 3
(1.2)
0–3.2 0.46
3rd-generation 
cephalosporin-
resistant E. coli
2,257
(17.5)
6.1–22.8 284
(17.9)
7.4–19.0 0.66 123
(33.4)
12.7–41.4 <0.01
Quinolone-resistant 
E. coli
4,227
(34.4)
15.2–40.1 453
(28.6)
15.4–40.5 <0.01 150
(41.6)
12.0–54.6 <0.01
Cephalosporin and 
quinolone-resistant
E. coli
1,080
(8.4)
0.8–19.9 181
(11.4)
5.7–15.3 <0.01 79
(21.4)
2.9–40.5 <0.01
3rd-generation 
cephalosporin-
resistant K.
pneumoniae
2,651
(35.9)
9.6–49.7 294
(30.6)
13.8–34.5 <0.01 187
(37.2)
8.8–46.6 0.54
Quinolone-resistant 
K. pneumoniae
3,074
(42.5)
11.5–58.3 321
(33.6)
11.1–39.6 <0.01 183
(36.7)
6.2–47.6 <0.01
Cephalosporin- and 
quinolone-resistant
K. pneumoniae
1,839
(24.9)
2.0–46.1 214
(22.3)
6.9–35.2 0.05 135
(26.2)
0.0–41.2 0.47
Carbapenem-
resistant P.
aeruginosa
477
(9.6)
2.4–12.2 45
(16.5)
9.1–23.1 <0.01 74
(18.3)
3.3–27.2 <0.01
Carbapenem-
resistant 
Acinetobacter spp.
929
(49.6)
16.9–65.5 86
(48.1)
18.2–66.7 0.66 164
(59.7)
31.6–68.8 <0.01
Multidrug-resistant
Acinetobacter spp.*
354
(18.2)
3.6–26.1 34
(17.8)
0.0–29.8 0.88 64
(23.4)
0.0–30.2 0.02
*ICU, represents all intensive care units, including surgical, medical, pediatric, and neonatal; S. aureus, Staphylococcus aureus; E. faecium or E. faecalis, 
Enterococcus faecium or Enterococcus faecalis; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas 
aeruginosa. Multidrug resistant is defined by resistance to ampicillin/sulbactam, carbapenems, all cephalosporins, aminoglycosides (gentamicin and 
amikacin), and ciprofloxacin. 
†No. resistant isolates (e.g., methicillin-resistant S. aureus, carbapenem-resistant P. aeruginosa) from all clinical specimens from all hospitals. The 
percentage in parenthesis refers to the proportion of resistant isolates over all isolates of the same species (resistant plus susceptible). 
‡Range of proportions of resistant isolates over all isolates of the same species obtained from individual hospitals, expressed as percentages. 
§p value for χ
2 test comparing proportion of resistant isolates in blood culture and non–blood culture isolates. 
¶p value for χ
2 test comparing proportion of resistant isolates in ICU vs. non–ICU culture isolates. DISPATCHES
Conclusions
This is the ﬁ  rst comprehensive national survey of an-
timicrobial drug resistance in Singapore public hospitals. 
We believe that our ﬁ  ndings represent the endemic anti-
microbial drug resistance situation in our hospitals; quar-
terly data analysis did not show any overt outbreak. These 
results, although new, are not surprising. Previous regional 
surveys and local studies had already hinted at the extent of 
the problem in Singapore (10–12). Similar data have also 
been reported from other countries in the Asia Paciﬁ  c re-
gion (10,11).
Use of both incidence density and percentage resistance 
enabled a more nuanced analysis of the scale of the prob-
lem. Although almost half of all Acinetobacter spp. clinical 
isolates were resistant to imipenem, the relative rarity of 
isolating this organism from clinical specimens renders it a 
smaller problem compared with MRSA or quinolone-resis-
tant Enterobacteriaceae outside the ICU setting.
In comparison with similar data from Europe (5) and 
Australia (4), prevalence of resistance in gram-negative or-
ganisms is much higher but prevalence of vancomycin-re-
sistant enterococci is lower. MRSA rates are comparable to 
those in some countries in southern Europe (5) but higher 
than those in Australia. The reasons for the differences in 
antimicrobial drug–resistant patterns might be related to in-
fection control practices or to timing of the introduction of 
resistant organisms. However, more research is needed to 
clarify these differences.
There are several limitations of this work. First, the in-
ability to segregate nosocomial and community infections 
prevented a more detailed analysis of antimicrobial drug–
resistance issues pertaining to community and hospital 
settings. Second, the use of different laboratory standards 
and methods potentially adds a degree of inaccuracy in the 
analyses. Third, routine laboratory data did not enable us 
to distinguish the different mechanisms of resistance, par-
ticularly among gram-negative bacteria, or to determine the 
presence of any predominant clone responsible for the high 
endemic levels of antimicrobial resistance.
Nevertheless, the results can serve to direct any na-
tional effort aimed toward reducing the antimicrobial resis-
tance problems of local hospitals. The issues of MRSA in 
general and carbapenem-resistant Acinetobacter spp. and 
P. aeruginosa in local ICUs are particularly pressing. Con-
tinued surveillance will also serve as an impartial feedback 
on the efforts of infection control programs for the future. 
For a small city-state, comprehensive national surveillance 
is relatively easier for Singapore than for larger countries. 
Such surveillance of clinical microbiology isolates is a 
critical ﬁ  rst step toward controlling the growing worldwide 
threat of antimicrobial drug resistance, and WHONET is a 
useful tool in this respect.
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